Probiotic BSH Activity and Anti-Obesity Potential of Lactobacillus plantarum Strain TCI378 Isolated from Korean Kimchi

Huang, Chu-Han; Ho, Cheng-Yu; Chen, Ciao-Ting; Hsu, Hsin-Fen; Lin, Yung-Hsiang

doi:10.3746/pnf.2019.24.4.434

Cited by 17 publications

(17 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: A B Csupporting

confidence: 91%

“…International studies shown that Lactobacillus plantarum had a quite substantial BSH-activity (Huang et al, 2019;Kumar, Grover & Batish, 2012;Ren, Sun, Wu, Yao & Guo, 2011;Tsai et al, 2014). In our present trial we also revealed, using quantitively assessment method (Huijghebaert & Hofmann, 1986;Joyce et al, 2014), a quite high BSH activity of investigational capsules containing 2*109 CFU in one capsule, that confirm and expand the literature data (Huang et al, 2019;Kumar et al, 2012;Ren et al, 2011;Tsai et al, 2014). After 12 weeks of our investigation it was shown that additional supplementation with probiotic L. plantarum led to statistically significant increasing of RA of gut bacterial BSH in patients with dyslipidemia that was similar to healthy adults without dyslipidemia.…”

Section: A B Cmentioning

confidence: 99%

“…With the lipid lowering aim, some investigations proposed to use the isolated form of BSH enzyme (Bi, Fang, Lu, Du &Chen, 2013;Sridevi, Vishwe & Prabhune, 2009) with promising results, but such approach is technically and economically inconvenient and has not been widely developed. But a lot of investigations on animal models (Kim et al, 2017;Yao, Tian, Song & Wang, 2020) and human trials (Costabile et al, 2017;Sharma, Kurpad & Puri, 2016;Wang et al, 2018;Wu, Zhang, Ren & Ruan, 2017) have revealed the hypocholesterolemic effect of different BSH-producing probiotic bacteria, for example different strains of Lactobacilli (Costabile et al, 2017;Huang, Ho, Chen, Hsu & Lin, 2019;Wang, Huang, Xia, Xiong & Ai, 2019;Wu et al, 2017;Yao et al, 2020). Our previous trial also shown that probiotic Lactobacillus plantarum may have effect in reducing levels of TC and LDL (Шипулін, Чернявський, Неверовський & Парунян, 2018).…”

mentioning

confidence: 94%

See 2 more Smart Citations

Modification of Gut Bacterial Bile Salt Hydrolase Activity and Cardiovascular Risk: A Randomized Study

Neverovskyi¹,

Chernyavskyi²,

Shypulin³

et al. 2020

USMYJ

View full text Add to dashboard Cite

Introduction: secretion of bacterial bile salt hydrolase (BSH) is one of the main mechanisms by which gut microbiota play role in cholesterol metabolism. There are limiting and controversial data regarding the clear effect of gut BSH activity correction on modification of serum cholesterol and cardiovascular risk (CVR). Aim of investigation was to evaluate the relationship between modification of the gut bacterial BSH relative activity (RA) by probiotic L. plantarum and serum cholesterol with CVR levels. Methods: the study was conducted as open, comparative, randomized, parallel and included 26 almost healthy participants (healthy control group) and 77 patients with dyslipidemia and without anamnesis of major cardiovascular events, that were divided in two groups: main treatment group (n=41) received combination therapy (capsules with Lactobacillus plantarum in the amount of 2*109 CFU one time a day and tablets simvastatin 20 mg one time a day) and control treatment group (n=36) received monotherapy (simvastatin 20 mg one time a day) during 12 weeks. Before and after 12 weeks of treatment the assessment of total RA of gut BSH, lipid profile and CVR level according to 5 risk scores were performed. Results: at baseline the RA of BSH was higher in healthy adults comparing to participants with dyslipidemia (p<0,001); after 12 weeks of treatment there wasn`t difference between healthy control and only main treatment groups (р=0,45). It was found that with increasing of RA of gut bacterial BSH, the risk of failure of treatment efficacy endpoints achievement (³20% reduction of values) decreased regarding: total cholesterol (TC) (p=0,0306), OR=0,00133 (95% CI; 3,28*10-6-0,538); low-density lipoproteins (LDL) (p<0,001), OR=5,65*10-14(95% CI; 6,38*10-20-5*10-8); CVR level according to Framingham score (р=0,0035), OR=4,09*10-5(95% CI; 4,66*10-8-0,0359); CVR level according to 2013 ACC/AHA algorithm (р=0,0135), OR=3,8*10-4(95% CI; 7,34*10-7-0,197); CVR level according to PROCAM score (p=0,00125), OR=8,38*10-6 (95%; CI; 6,93*10-9-0,0101). Conclusions: additional supplementation with BSH-producing bacteria L. plantarum was more effective in increasing of BSH activity compared to simvastatin monotherapy. Increasing of BSH RA by L. plantarum was associated with higher chances to achieve treatment efficacy goals regarding reduction of TC, LDL and CVR levels according to Framingham, 2013 ACC/AHA algorithm and PROCAM scores.

show abstract

Section: A B Csupporting

confidence: 91%

Section: A B Cmentioning

confidence: 99%

mentioning

confidence: 94%

See 1 more Smart Citation

Modification of Gut Bacterial Bile Salt Hydrolase Activity and Cardiovascular Risk: A Randomized Study

Neverovskyi¹,

Chernyavskyi²,

Shypulin³

et al. 2020

USMYJ

View full text Add to dashboard Cite

show abstract

“…Similarly, a probiotic mixture containing B. animalis VLK and VKB and L. casei IMV B-7280 increased the levels of IL-4, IL-10 and TGF-β in rats with monosodium glutamate-induced obesity (Falalyeyeva et al, 2017). In this vein, L. plantarum was shown as a promising strain for the reduction of hypercholesterolemia and adipogenesis in vitro experiments (Huang et al, 2019).…”

Section: Discussionmentioning

confidence: 92%

Probiotics as a therapeutic strategy in obesity and overweight: a systematic review

Tomé-Castro

Rodriguez‐Arrastia

Cardona

et al. 2021

View full text Add to dashboard Cite

Obesity and overweight are two of the most health challenges with an increasing prevalence in recent years, in which several complications have been identified to have a high impact in patients’ health conditions. In this vein, an increasing interest in the gut microbiota has emerged as a target for therapeutic strategies in obesity and overweight due to its direct relation with the aforementioned health conditions and complications. Thus, the aim of this study was to evaluate the efficacy of probiotics as a therapeutic strategy in the management of obesity and overweight. A systematic review of randomised controlled trials was carried out in 6 databases until May 2019 to assess the use of probiotics in obesity and overweight patients. The Jadad Scale was used to assess the quality of the clinical trials. Twenty-three clinical trials published between 2000 and 2019 met the inclusion criteria. The role of probiotics in reducing body mass index and weight as well as changing the visceral abdominal fat area, waist and hip circumference were shown in 14 of 23 trials (60.87%); 14 trials (60.87%) showed changes on patients’ fatty acids and biomarkers; and 4 trials (17.39%) studied the role of the gut microbiota in obese and overweight patients. Some probiotics strains are shown to be effective in reducing body mass index and hip circumference. This review provides evidence of successful results in weight loss using probiotic groups.

show abstract

“…Some of the reported beneficial effects of probiotics in human health include anticancer [99][100][101][102][103][104][105][106][107][108][109][110][111], anti-allergic [112,113], anti-diabetic [114][115][116], anti-obesity [117][118][119][120], anti-pathogenic [121,122], immunomodulatory [123], and anti-inflammatory [124][125][126][127] activities [128], as reported in Table 1.…”

Section: Health Promoting Effect Of Prebiotics Probiotics and Synbimentioning

confidence: 99%

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

Durazzo

Nazhand

Lucarini

et al. 2020

IJMS

View full text Add to dashboard Cite

Over the last few years, the application of nanotechnology to nutraceuticals has been rapidly growing due to its ability to enhance the bioavailability of the loaded active ingredients, resulting in improved therapeutic/nutraceutical outcomes. The focus of this work is nanoprebiotics and nanoprobiotics, terms which stand for the loading of a set of compounds (e.g., prebiotics, probiotics, and synbiotics) in nanoparticles that work as absorption enhancers in the gastrointestinal tract. In this manuscript, the main features of prebiotics and probiotics are highlighted, together with the discussion of emerging applications of nanotechnologies in their formulation. Current research strategies are also discussed, in particular the promising use of nanofibers for the delivery of probiotics. Synbiotic-based nanoparticles represent an innovative trend within this area of interest. As only few experimental studies on nanoprebiotics and nanoprobiotics are available in the scientific literature, research on this prominent field is needed, covering effectiveness, bioavailability, and safety aspects.

show abstract

Probiotic BSH Activity and Anti-Obesity Potential of Lactobacillus plantarum Strain TCI378 Isolated from Korean Kimchi

Cited by 17 publications

References 65 publications

Modification of Gut Bacterial Bile Salt Hydrolase Activity and Cardiovascular Risk: A Randomized Study

Modification of Gut Bacterial Bile Salt Hydrolase Activity and Cardiovascular Risk: A Randomized Study

Probiotics as a therapeutic strategy in obesity and overweight: a systematic review

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

Contact Info

Product

Resources

About